Humacyte has secured up to $150 million in new capital – including $40 million upfront – from Oberland Capital Management as the firm moves to commercialize bioengineered human tissue. Here are the details.
Read More
Bioengineering startup Humacyte has secured $50 million in debt financing from Silicon Valley Bank as it prepares to go public through a SPAC merger with Alpha Healthcare Acquisition Corp.
Read More
Humacyte, a regenerative medicine company based in Durham, has demonstrated that its human acellular vessels (HAVs) repopulate with a patient’s own cells to form a living vascular tissue.
Read MoreLife science startup Humacyte, which has generated worldwide interest in its bioengineering technology, has landed $150 million in equity from Boston-based Fresenius Medical Care
Read More
